摘要
目的 :用99m锝 甲氰基异丁基晴心肌灌注断层显像 (SPECT) ,评价参麦注射液对急性心肌梗死 (AMI)尿激酶 (UK)溶栓治疗再灌注心肌保护作用的临床疗效。方法 :537例AMI患者随机分为两组 ,参麦组 ( 2 92例 )采用UK溶栓疗法和参麦注射液治疗 ,对照组 ( 2 4 5例 )只使用UK溶栓疗法。于溶栓治疗后第7日进行SPECT检测。对两组心肌缺血面积 (IMA)和左室射血分数 (EF)的变化进行对比研究。结果 :参麦组和对照组梗塞相关血管 (IRA)再通率之间差异无显著性 (分别为 72 2 6%、72 65% ,P >0 0 5)。参麦组IRA再通患者 ( 2 11例 )的IMA显著低于对照组IRA再通患者 ( 178例 ,P <0 0 1)。参麦组IRA未通患者( 81例 )的IMA与对照组 ( 67例 )比较 ,亦显著降低 (P <0 0 5)。参麦组EF显著高于对照组 (P <0 0 1)。结论 :在AMIUK溶栓治疗早期使用参麦注射液可显著缩减IMA ,提高EF。
Objective: To evaluate the myocardial protecting effect of Shenmai injection (SMI) against ischemia/reperfusion injury in thrombolytic therapy with urokinase (UK) for acute myocardial infarction patients by 99m Tc MIBI myocardial imaging (SPECT). Methods: Five hundred and thirty seven patients were randomly divided into two groups. The SMI group (n=292) was treated with thrombolytic treatment plus SMI and the control group (n=245) with thrombolytic treatment only. Single photon emission computerized tomography (SPECT) was carried out on the 7th day after thrombolysis to determine the ischemic myocardial area (IMA) and ejection fraction (EF) in both groups and compared. Results: The reperfusion rate of infarction related area (IRA) in the two groups was not different significantly (72.26% vs 72.65%, P>0 05). The IMA in patients of the SMI group, no matter with or without reperfused IRA (211 cases and 81 cases) respectively, was significantly lower than that in the control group (178 cases and 67 cases) respectively, P<0 01 and P<0 05 respectively. The EF value in the SMI group was significantly higher than that in the control group (P<0 01). Conclusion: Using SMI in early stage of thrombolytic treatment in acute myocardial infarction could significantly reduce IMA and increase EF. SMI showed good protective effect against myocardial ischemia/reperfusion injury in thrombolytic treatment.
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2001年第2期108-110,共3页
Chinese Journal of Integrated Traditional and Western Medicine
